James Rucker

Senior Clinical Lecturer at King's College London

Data updated

Papers

28 publications

Trials

0 clinical trials

Research Footprint

James Rucker appears in 28 tracked papers (2016–2026), most studied alongside Psilocybin, 5-MeO-DMT and LSD, across Depressive Disorders, Safety & Risk Management and Anxiety Disorders.

Most-cited paper: Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study (1520 citations).

Frequent co-authors: Allan Young, Mathieu Seynaeve and Fiona Dunbar.

Background & Research

James Rucker is a consultant psychiatrist and leading trialist in the UK. He heads the Psychedelic Trials Group at the Institute of Psychiatry, Psychology & Neuroscience, where he conducts clinical trials on psilocybin, MDMA, and ketamine. His work focuses on integrating these pharmacological breakthroughs with psychotherapeutic frameworks for psychiatric recovery.

Key Impact

Leads the Psychedelic Trials Group investigating psilocybin for treatment-resistant depression.

28

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

49 collaborators· click a node to visit their profile

Full network →

Compounds

Psilocybin5-MeO-DMTLSDAyahuascaMDMADMTMescalineKetamine

Topics

Depressive DisordersSafety & Risk ManagementAnxiety DisordersTreatment-Resistant Depression (TRD)Substance Use Disorders (SUD)Major Depressive Disorder (MDD)Chronic PainPTSDHeadache Disorders (Cluster & Migraine)Palliative & End-of-Life DistressHealthy VolunteersSet & SettingPersonality & Trait FactorsObsessive-Compulsive Disorder (OCD)Alcohol Use Disorder (AUD)Medicinal Chemistry & Drug DevelopmentInterpersonal Functioning & Social ConnectednessPublic Health, Prevention & Behaviour ChangeAdolescentsTobacco/Nicotine Use Disorder (TUD)SchizophreniaOlder AdultsNeurocognitive DisordersMicrodosingPeripartumNeuroimaging & Brain MeasuresEquity and EthicsSuicidalityNeurological Injury

Top Collaborators

Affiliations

Institutions, companies, and organisations James Rucker is associated with.

King's College London

academic

The Centre for Mental Health Research and Innovation and the Psychoactive Trials Group are actively conducting clinical trials with various psychedelic compounds to develop new care models for treatment-resistant depression, PTSD, and anorexia nervosa.

View stakeholder →